BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/19/2021 2:10:40 PM | Browse: 509 | Download: 711
 |
Received |
|
2021-01-28 18:35 |
|
Peer-Review Started |
|
2021-01-28 18:38 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-03-29 02:07 |
|
Revised |
|
2021-04-12 14:41 |
|
Second Decision |
|
2021-07-05 05:45 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-07-05 09:48 |
|
Articles in Press |
|
2021-07-05 09:48 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-07-15 08:10 |
|
Publish the Manuscript Online |
|
2021-07-19 14:10 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Surgery |
| Manuscript Type |
Minireviews |
| Article Title |
Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ahmad Hamad, Zachary J Brown, Aslam M Ejaz, Mary Dillhoff and Jordan M Cloyd |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jordan M Cloyd, MD, Assistant Professor, Department of Surgery, The Ohio State University Wexner Medical Center, 410 W 10th Ave, N907 Doan Hall, Columbus, OH 43215, United States. jordan.cloyd@osumc.edu |
| Key Words |
Pancreatic cancer; Preoperative therapy; FOLFIRINOX; Precision oncology; Patient-reported outcomes; Personalized medicine; Targeted therapy; Whipple; Pancreatectomy |
| Core Tip |
Neoadjuvant therapy (NT) is an increasingly utilized approach that maximizes the receipt of multimodality therapy, improves margin-negative resection rates, and potentially increases survival durations. In the era of personalized medicine, the neoadjuvant period can also be used to emphasize precision oncology. Already, current methods of anatomically staging, molecularly profiling, and monitoring response to therapy can be used to personalize neoadjuvant treatment for localized pancreatic ductal adenocarcinoma (PDAC). In this article, we describe the current evidence for the use of NT and highlight unique opportunities for personalized care in patients with PDAC undergoing NT. |
| Publish Date |
2021-07-19 14:10 |
| Citation |
Hamad A, Brown ZJ, Ejaz AM, Dillhoff M, Cloyd JM. Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care. World J Gastroenterol 2021; 27(27): 4383-4394 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i27/4383.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i27.4383 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
